Pulmatrix (PULM) 8-K Pulmatrix Reports Q1 2019 Results

Exhibit 99.1

May 15, 2019

Pulmatrix Reports Q1 2019 Results

LEXINGTON, MA –Pulmatrix, Inc. (NASDAQ: PULM) today reports its first quarter results.

“We reached a major milestone in the first quarter with the FDA providing approval to begin our planned Pulmazole Phase 2 clinical trial. With the closing of our recent financing in April and receipt of the upfront payment from Cipla related to the Definitive Agreement for theco-development and commercialization of Pulmazole, we currently have a cash balance of approximately $37 million which fully funds Pulmatrix beyond the completion of the Phase 2 trial that will begin this quarter”, saidRobert W. Clarke, Ph.D., chief executive officer of Pulmatrix.

Financials

As of March 31, 2019, Pulmatrix had $2.1 million in cash, compared to $2.6 million as of December 31, 2018. In April 2019, Pulmatrix completed a financing that resulted in $16.6 million total gross proceeds and executed a Definitive Agreement with Cipla for theco-development and commercialization of Pulmazole. In early May 2019, Pulmatrix received a $22 million upfront payment from Cipla. Following the completion of planned Phase 2 clinical trial, both parties will equally share costs related to the future development and commercialization of Pulmazole and will equally share worldwide free cash flow from future sales of Pulmazole.

Pulmatrix generated no revenue in the first quarter of 2019, compared to $0.2 million of revenues in the first quarter of 2018. The revenue for the first quarter of 2018 resulted from the Cystic Fibrosis Foundation Therapeutics award related to our Pulmazole program.

Research and development expenses for the first quarter of 2019 were $2.2 million, compared to $3.2 million for the same period last year. The increase was primarily due to decreases in clinical development costs and external service costs on the PUR1800 project. General and administrative expenses for both the first quarter of 2019 and the first quarter of 2018 were $2.0 million.

Net loss was $5.2 million for both the first quarter of 2019 and the first quarter of 2018.

About Pulmatrix

Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company’s proprietary product pipeline is focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis (“ABPA”), and PUR1800, a narrow spectrum kinase inhibitor for patients with obstructive lung diseases including asthma and chronic obstructive pulmonary disease (“COPD”). Pulmatrix’s product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.

FORWARD-LOOKING STATEMENTS

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements of historical fact, and may be identified by words such as “anticipates,” “assumes,” “believes,” “can,” “could,” “estimates,” “expects,” “forecasts,” “guides,” “intends,” “is confident that”, “may,” “plans,” “seeks,” “projects,” “targets,” and “would,” and their opposites and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company’s ability to

manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company’s products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company’s filings with the SEC, including its annual report on Form10-K filed with the Securities and Exchange Commission on February 19, 2019, as may be supplemented or amended by the Company’s Quarterly Reports on Form10-Q. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

###

Financial Tables to Follow

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

	At March 31, 2019			At December 31, 2018
	(unaudited)
Assets
Current assets:
Cash	$	2,146		$	2,563
Prepaid expenses and other current assets		1,236			717
Total current assets		3,382			3,280
Property and equipment, net		354			394
Long-term restricted cash		204			204
Goodwill		10,051			10,845
Total assets	$	13,991		$	14,723
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	1,611		$	1,183
Accrued expenses		2,184			1,696
Total current liabilities		3,795			2,879
Stockholders’ equity:
Common stock, $0.0001 par value — 200,000,000 shares authorized; 8,027,895 and 4,932,723 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively		1			—
Additionalpaid-in capital		209,916			206,409
Accumulated deficit		(199,721	)		(194,565	)
Total stockholders’ equity		10,196			11,844
Total liabilities, redeemable convertible preferred stock and stockholders’ equity	$	13,991		$	14,723

CONDENSED CONSOLIDATED RESULTS OF OPERATIONS

(unaudited)

(in thousands, except share and per share data)

	For the Three Months Ended March 31,
	2019			2018
Revenues	$	—		$	153
Operating expenses
Research and development		2,176			3,221
General and administrative		1,987			2,046
Impairment of goodwill		794			—
Total operating expenses		4,957			5,267
Loss from operations		(4,957	)		(5,114	)
Interest expense		—			(106	)
Settlement expense		(200	)		—
Other income (expense), net		1			(1	)
Net loss	$	(5,156	)	$	(5,221	)
Net loss per share attributable to common stockholders, basic and diluted	$	(0.74	)	$	(2.39	)
Weighted average shares used to compute basic and diluted net loss per share attributable to common stockholders		6,944,513			2,187,699

###

Investor Contact
Robert Clarke, CEO	William Duke, CFO
(781)357-2333	(781)357-2333
rclarke@pulmatrix.com	wduke@pulmatrix.com